Prognostic value of serial b-type natriuretic peptide measurement in transcatheter aortic valve replacement (from the PARTNER Trial)

Brian P. O'Neill, Mayra Guerrero, Vinod H. Thourani, Susheel Kodali, Alan Heldman, Mathew Williams, Ke Xu, Augusto Pichard, Michael Mack, Vasilis Babaliaros, Howard C. Herrmann, John Webb, Pamela S. Douglas, Martin B. Leon, William W. O'Neill

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

B-type natriuretic peptide (BNP) levels have shown a correlation with outcomes in studies of aortic valve surgery. Results from multicenter trials of BNP in transcatheter aortic valve surgery (TAVR) are lacking. The aim of this study was to investigate the prognostic role of serial measurement of BNP in transfemoral TAVR. A total of 1,097 patients who underwent TAVR via transfemoral access were analyzed by tertile of baseline BNP. Of those, 933 with BNP levels at 30 days were divided into 2 groups on the basis of increases (334 patients) or decreases or no change (599 patients) in BNP compared with baseline. Patients in the low-tertile BNP group had a lower rate of death at 1 year than those in the higher tertile group (15.0% vs 23.0%, p <0.01) which was not significant in multivariate analysis. Over 1 year, BNP decreased from 1,258.13 ± 2,988.33 to 594.37 ± 1,087.30 (p <0.01) in the entire group. Patients in the BNP-rise group had higher rates of death at 1 year (20.3% vs 11.4%, p <0.01) and an overall increase in moderate or severe aortic regurgitation over 1 year (p <0.01). Multivariate predictors of 1-year mortality were moderate or severe aortic regurgitation (hazard ratio 2.04, 95% confidence interval 1.36 to 3.05, p <0.01), increase in BNP at 30 days (hazard ratio 1.82, 95% confidence interval 1.26 to 2.62, p <0.01) and Society of Thoracic Surgeons score (hazard ratio 1.05, 95% confidence interval 1.01 to 1.10, p = 0.03). In conclusion, increase in BNP at 30 days from baseline and moderate or severe aortic regurgitation at 30 days in patients who undergo transfemoral TAVR are independently associated with 1-year mortality. Increase in BNP at 30 days should prompt evaluation for causes of elevated wall stress, including aortic regurgitation.

Original languageEnglish (US)
Pages (from-to)1265-1272
Number of pages8
JournalAmerican Journal of Cardiology
Volume115
Issue number9
DOIs
StatePublished - May 1 2015
Externally publishedYes

Fingerprint

Natriuretic Peptides
Brain Natriuretic Peptide
Aortic Valve
Aortic Valve Insufficiency
Mortality
Confidence Intervals
Transcatheter Aortic Valve Replacement
Multicenter Studies
Multivariate Analysis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Prognostic value of serial b-type natriuretic peptide measurement in transcatheter aortic valve replacement (from the PARTNER Trial). / O'Neill, Brian P.; Guerrero, Mayra; Thourani, Vinod H.; Kodali, Susheel; Heldman, Alan; Williams, Mathew; Xu, Ke; Pichard, Augusto; Mack, Michael; Babaliaros, Vasilis; Herrmann, Howard C.; Webb, John; Douglas, Pamela S.; Leon, Martin B.; O'Neill, William W.

In: American Journal of Cardiology, Vol. 115, No. 9, 01.05.2015, p. 1265-1272.

Research output: Contribution to journalArticle

O'Neill, BP, Guerrero, M, Thourani, VH, Kodali, S, Heldman, A, Williams, M, Xu, K, Pichard, A, Mack, M, Babaliaros, V, Herrmann, HC, Webb, J, Douglas, PS, Leon, MB & O'Neill, WW 2015, 'Prognostic value of serial b-type natriuretic peptide measurement in transcatheter aortic valve replacement (from the PARTNER Trial)', American Journal of Cardiology, vol. 115, no. 9, pp. 1265-1272. https://doi.org/10.1016/j.amjcard.2015.01.561
O'Neill, Brian P. ; Guerrero, Mayra ; Thourani, Vinod H. ; Kodali, Susheel ; Heldman, Alan ; Williams, Mathew ; Xu, Ke ; Pichard, Augusto ; Mack, Michael ; Babaliaros, Vasilis ; Herrmann, Howard C. ; Webb, John ; Douglas, Pamela S. ; Leon, Martin B. ; O'Neill, William W. / Prognostic value of serial b-type natriuretic peptide measurement in transcatheter aortic valve replacement (from the PARTNER Trial). In: American Journal of Cardiology. 2015 ; Vol. 115, No. 9. pp. 1265-1272.
@article{82e0925be6b84c6daa50ce8c24fc15bd,
title = "Prognostic value of serial b-type natriuretic peptide measurement in transcatheter aortic valve replacement (from the PARTNER Trial)",
abstract = "B-type natriuretic peptide (BNP) levels have shown a correlation with outcomes in studies of aortic valve surgery. Results from multicenter trials of BNP in transcatheter aortic valve surgery (TAVR) are lacking. The aim of this study was to investigate the prognostic role of serial measurement of BNP in transfemoral TAVR. A total of 1,097 patients who underwent TAVR via transfemoral access were analyzed by tertile of baseline BNP. Of those, 933 with BNP levels at 30 days were divided into 2 groups on the basis of increases (334 patients) or decreases or no change (599 patients) in BNP compared with baseline. Patients in the low-tertile BNP group had a lower rate of death at 1 year than those in the higher tertile group (15.0{\%} vs 23.0{\%}, p <0.01) which was not significant in multivariate analysis. Over 1 year, BNP decreased from 1,258.13 ± 2,988.33 to 594.37 ± 1,087.30 (p <0.01) in the entire group. Patients in the BNP-rise group had higher rates of death at 1 year (20.3{\%} vs 11.4{\%}, p <0.01) and an overall increase in moderate or severe aortic regurgitation over 1 year (p <0.01). Multivariate predictors of 1-year mortality were moderate or severe aortic regurgitation (hazard ratio 2.04, 95{\%} confidence interval 1.36 to 3.05, p <0.01), increase in BNP at 30 days (hazard ratio 1.82, 95{\%} confidence interval 1.26 to 2.62, p <0.01) and Society of Thoracic Surgeons score (hazard ratio 1.05, 95{\%} confidence interval 1.01 to 1.10, p = 0.03). In conclusion, increase in BNP at 30 days from baseline and moderate or severe aortic regurgitation at 30 days in patients who undergo transfemoral TAVR are independently associated with 1-year mortality. Increase in BNP at 30 days should prompt evaluation for causes of elevated wall stress, including aortic regurgitation.",
author = "O'Neill, {Brian P.} and Mayra Guerrero and Thourani, {Vinod H.} and Susheel Kodali and Alan Heldman and Mathew Williams and Ke Xu and Augusto Pichard and Michael Mack and Vasilis Babaliaros and Herrmann, {Howard C.} and John Webb and Douglas, {Pamela S.} and Leon, {Martin B.} and O'Neill, {William W.}",
year = "2015",
month = "5",
day = "1",
doi = "10.1016/j.amjcard.2015.01.561",
language = "English (US)",
volume = "115",
pages = "1265--1272",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "9",

}

TY - JOUR

T1 - Prognostic value of serial b-type natriuretic peptide measurement in transcatheter aortic valve replacement (from the PARTNER Trial)

AU - O'Neill, Brian P.

AU - Guerrero, Mayra

AU - Thourani, Vinod H.

AU - Kodali, Susheel

AU - Heldman, Alan

AU - Williams, Mathew

AU - Xu, Ke

AU - Pichard, Augusto

AU - Mack, Michael

AU - Babaliaros, Vasilis

AU - Herrmann, Howard C.

AU - Webb, John

AU - Douglas, Pamela S.

AU - Leon, Martin B.

AU - O'Neill, William W.

PY - 2015/5/1

Y1 - 2015/5/1

N2 - B-type natriuretic peptide (BNP) levels have shown a correlation with outcomes in studies of aortic valve surgery. Results from multicenter trials of BNP in transcatheter aortic valve surgery (TAVR) are lacking. The aim of this study was to investigate the prognostic role of serial measurement of BNP in transfemoral TAVR. A total of 1,097 patients who underwent TAVR via transfemoral access were analyzed by tertile of baseline BNP. Of those, 933 with BNP levels at 30 days were divided into 2 groups on the basis of increases (334 patients) or decreases or no change (599 patients) in BNP compared with baseline. Patients in the low-tertile BNP group had a lower rate of death at 1 year than those in the higher tertile group (15.0% vs 23.0%, p <0.01) which was not significant in multivariate analysis. Over 1 year, BNP decreased from 1,258.13 ± 2,988.33 to 594.37 ± 1,087.30 (p <0.01) in the entire group. Patients in the BNP-rise group had higher rates of death at 1 year (20.3% vs 11.4%, p <0.01) and an overall increase in moderate or severe aortic regurgitation over 1 year (p <0.01). Multivariate predictors of 1-year mortality were moderate or severe aortic regurgitation (hazard ratio 2.04, 95% confidence interval 1.36 to 3.05, p <0.01), increase in BNP at 30 days (hazard ratio 1.82, 95% confidence interval 1.26 to 2.62, p <0.01) and Society of Thoracic Surgeons score (hazard ratio 1.05, 95% confidence interval 1.01 to 1.10, p = 0.03). In conclusion, increase in BNP at 30 days from baseline and moderate or severe aortic regurgitation at 30 days in patients who undergo transfemoral TAVR are independently associated with 1-year mortality. Increase in BNP at 30 days should prompt evaluation for causes of elevated wall stress, including aortic regurgitation.

AB - B-type natriuretic peptide (BNP) levels have shown a correlation with outcomes in studies of aortic valve surgery. Results from multicenter trials of BNP in transcatheter aortic valve surgery (TAVR) are lacking. The aim of this study was to investigate the prognostic role of serial measurement of BNP in transfemoral TAVR. A total of 1,097 patients who underwent TAVR via transfemoral access were analyzed by tertile of baseline BNP. Of those, 933 with BNP levels at 30 days were divided into 2 groups on the basis of increases (334 patients) or decreases or no change (599 patients) in BNP compared with baseline. Patients in the low-tertile BNP group had a lower rate of death at 1 year than those in the higher tertile group (15.0% vs 23.0%, p <0.01) which was not significant in multivariate analysis. Over 1 year, BNP decreased from 1,258.13 ± 2,988.33 to 594.37 ± 1,087.30 (p <0.01) in the entire group. Patients in the BNP-rise group had higher rates of death at 1 year (20.3% vs 11.4%, p <0.01) and an overall increase in moderate or severe aortic regurgitation over 1 year (p <0.01). Multivariate predictors of 1-year mortality were moderate or severe aortic regurgitation (hazard ratio 2.04, 95% confidence interval 1.36 to 3.05, p <0.01), increase in BNP at 30 days (hazard ratio 1.82, 95% confidence interval 1.26 to 2.62, p <0.01) and Society of Thoracic Surgeons score (hazard ratio 1.05, 95% confidence interval 1.01 to 1.10, p = 0.03). In conclusion, increase in BNP at 30 days from baseline and moderate or severe aortic regurgitation at 30 days in patients who undergo transfemoral TAVR are independently associated with 1-year mortality. Increase in BNP at 30 days should prompt evaluation for causes of elevated wall stress, including aortic regurgitation.

UR - http://www.scopus.com/inward/record.url?scp=84927549107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927549107&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2015.01.561

DO - 10.1016/j.amjcard.2015.01.561

M3 - Article

C2 - 25863422

AN - SCOPUS:84927549107

VL - 115

SP - 1265

EP - 1272

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 9

ER -